Rilotumumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.

Clinical Use

A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.

Rilotumumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Rilotumumab Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354; +17819995354	marketing@targetmol.com	United States	32376	58
Aladdin Scientific		tp@aladdinsci.com	United States	57505	58
Shanghai YuanYe Biotechnology Co., Ltd.	021-61312847; 18021002903	3008007409@qq.com	China	71826	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7972	62
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24982	58
Biolab Reagents	18108604356	info@biolabreagent.com	China	9868	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	6204	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11973	58

---

• Rilotumumab
• Research Grade Rilotumumab(DHD03702)
• Rilotumumab (anti-HGF)
• AMG 102
• Research Grade Rilotumumab
• 872514-65-3